Early trial for advanced cancers using HTL0039732
Part of Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Lungs & breathing, Women’s health & pregnancy clinical trials.
This is a Phase 1/2 study testing how well HTL0039732 works and is tolerated in people with advanced solid tumors that have not responded to standard treatments. It may help by offering a new treatment option and learning which cancer types and body markers respond best.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be able to sign consent and follow study visits and treatments
- Have an advanced solid tumor that has stopped responding to standard treatment (or no standard option is suitable)
- Have at least one tumor spot that can be measured on scans (or, for some cancers, an “assessable” spot)
- Be well enough to take part: age 18+, and body-function score (ECOG) of 0 or 1, with expected survival of at least ~3 months
- Have recent or available tumor tissue for testing (archival tissue is allowed; a new biopsy may be requested)
- Follow timing rules: no chemo/radiotherapy (except some pain-relief radiation) or other cancer medicines in the prior ~4 weeks; no immunotherapy dose in the prior ~12 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests the cancer medicines atezolizumab and tiragolumab in people with different solid tumors. It aims to see how well these drugs work and what side effects they cause in specific patient groups.
This trial tests a new drug, GSK5533524, alone or with other treatments, for people with advanced solid tumors that have stopped responding to standard therapies. It aims to find out if the drug is safe and shows early signs of working.
This study tests a new drug called GSK5764227 for people with advanced solid tumors. It aims to see if the drug is safe and works against cancer that has stopped responding to other treatments.
This study tests new drug combinations for people with various advanced cancers that have progressed after standard treatment, or in some cases, as a first treatment. It aims to see if these combinations are safe and effective. The study is divided into groups based on cancer type and treatment history, so not everyone will qualify for every group.
This trial tests a new drug called LAT010 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective.
This early-phase study tests whether HB0036 is safe and can work in people with advanced solid tumors (cancers) that have come back or spread and did not respond to standard treatments. You may be considered especially if your tumor matches certain tumor types and biomarker results.
Hear when a new Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.